- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 01.05. | Dimerix and Amicus to commercialise DMX-200 in US | ||
| 01.05. | End-to-end solutions: why every link in the pharmaceutical supply chain counts | ||
| 01.05. | GSK remains resilient on tariffs as Q1 sales rise 4% | ||
| 01.05. | Novartis to strengthen renal disease portfolio with Regulus | ||
| 01.05. | FDA approves J&J's Imaavy for generalised myasthenia gravis | ||
| 01.05. | Investors insist halted biotech IPOs will return in 2025 | ||
| 30.04. | Biopharma venture financing declines 20.2% YOY in Q1 2025 amid persistent investor caution | ||
| 30.04. | Boehringer, Oxford University and Cumulus to explore brain activity in BPD | ||
| 30.04. | Trump's first 100 days tout US-bound pharma investments amid tariff worries | ||
| 30.04. | Donald Trump's first 100 days: Impact on the healthcare industry | ||
| 30.04. | Magazine: The GLP-1 shortage is over. What's next for compounders? | ||
| 30.04. | FDA approves AbbVie's upadacitinib for giant cell arteritis | ||
| 30.04. | FDA approves Abeona's $3.1m cell therapy for rare skin disease | ||
| 30.04. | AstraZeneca's Truqap fails in another Phase III trial | ||
| 30.04. | Impending US tariffs signal uncertain future for global pharma, says GlobalData | ||
| 30.04. | Construction begins on MSD's $1bn biologics centre in Delaware, US | ||
| 30.04. | US tariffs likely to disrupt drug development costs and prices, says GlobalData | ||
| 30.04. | Myostatin inhibitors target muscle loss prevention to fill gap in GLP-1RA market | ||
| 29.04. | AstraZeneca CEO calls for increased European investment in pharma | ||
| 29.04. | Small biotechs shoulder the burdens of an uncertain biopharma sector | ||
| 29.04. | UK MHRA authorises BridgeBio's acoramidis for ATTR-CM | ||
| 29.04. | Biohaven secures $600m financing as it awaits FDA prodrug decision | ||
| 29.04. | Prilenia and Ferrer to commercialise pridopidine in Europe | ||
| 29.04. | EC conditionally approves Regeneron's Lynozyfic for multiple myeloma | ||
| 28.04. | J&J's Tremfya gains EC marketing authorisation for ulcerative colitis |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .